Download PDF
Horm Metab Res 2006; 38(11): 758-760
DOI: 10.1055/s-2006-955088
Original Clinical

© Georg Thieme Verlag KG Stuttgart · New York

Plasma Aminopeptidase Activities in Parkinson's Disease

I. Banegas 1 , F. Barrero 2 , R. Durán 3 , B. Morales 2 , J. D. Luna 3 , I. Prieto 1 , M. Ramírez 1 , F. Alba 3 , F. Vives 3
  • 1Unit of Physiology, Department of Health Sciences, University of Jaén, Spain
  • 2Alteration Movement Unit of the University Hospital of Granada, Spain
  • 3Institute of Neuroscience “Federico Oloriz”, University of Granada, Granada, Spain
Further Information

Publication History

Received 3 April 2006

Accepted after revision 23 May 2006

Publication Date:
16 November 2006 (online)

Also available at
    Permissions and Reprints

Abstract

Parkinson's disease (PD) is an age-related neurodegenerative disease characterized by a progressive motor disorder, but frequently is accompanied by autonomic symptoms such as hypotension. Together with the decrease of dopamine, significant decreases in aminopeptidase activities have been reported in PD brains. However, up to date there are no studies about changes of aminopeptidase activities in plasma of PD patients. We studied plasma activities of alanyl-, aspartyl-(AspAP), cystinyl-(CysAP) and glutamyl-aminopeptidase (GluAP) in two groups of subjects: control (n=41) and PD (n=48). Plasma activities of AspAP, CysAP, and GluAP showed significant decreases of 24.9% (p<0.05), 39.4% (p<0.01) and 33.3% (p<0.01), respectively, in PD group. These aminopeptidases are involved in the metabolism of circulating peptides such as the ones of the renin-angiotensin system. The importance of aminopeptidases in striatal dopamine content and in neuroendocrine system in PD is discussed.

Key words

Aminopeptidases - renin-angiotensin system - Parkinson's disease

References

  • 1 Zhang J, Goodlett DR, Montine TJ. Proteomic biomarker discovery in cerebrospinal fluid for neurodegenerative diseases.  J Alzheimers Dis. 2005;  8 377-386
    PubMedSearch in Google Scholar
  • 2 Micieli G, Tosi P, Marcheselli S, Cavallini A. Autonomic dysfunction in Parkinson's disease.  Neurol Sci. 2003;  24 ((Suppl 1)) S32-S34
    CrossrefPubMedSearch in Google Scholar
  • 3 Gonzalez De Aguilar JL, Rene F, Dupuis L, Loeffler JP. Neuroendocrinology of neurodegenerative diseases. Insights from transgenic mouse models.  Neuroendocrinology. 2003;  78 244-252
    CrossrefPubMedSearch in Google Scholar
  • 4 Banegas I, Ramirez M, Vives F, Alba F, Segarra AB, Duran R, De Gasparo M, Prieto I. Aminopeptidase activity in the nigrostriatal system and prefrontal cortex of rats with experimental hemiparkinsonism.  Horm Metab Res. 2005;  37 53-55
    Thieme ConnectPubMedSearch in Google Scholar
  • 5 Banegas I, Prieto I, Vives F, Alba F, Duran R, Segarra AB, de Gasparo M, Ramirez M. Plasma aminopeptidase activities in rats after left and right intrastriatal administration of 6-hydroxydopamine.  Neuroendocrinology. 2004;  80 219-224
    CrossrefPubMedSearch in Google Scholar
  • 6 Mantle D, Falkous G, Ishiura S, Perry RH, Perry EK. Comparison of cathepsin protease activities in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease.  J Neurol Sci. 1995;  131 65-70
    CrossrefPubMedSearch in Google Scholar
  • 7 Agil A, Durán R, Barrero F, Morales B, Araúzo M, Alba F, Miranda MT, Prieto I, Ramírez M, Vives F. Plasma lipid peroxidation in sporadic Parkinson's disease.  J Neurol Sci. 2006;  240 31-36
    CrossrefPubMedSearch in Google Scholar
  • 8 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.  Anal Biochem. 1976;  72 248-254
    CrossrefPubMedSearch in Google Scholar
  • 9 Li ST, Dendi R, Holmes C, Goldstein DS. Progressive loss of cardiac sympathetic innervation in Parkinson's disease.  Ann Neurol. 2002;  52 220-223
    CrossrefPubMedSearch in Google Scholar
  • 10 Otake K, Oiso Y, Mitsuma T, Hirooka Y, Adachi K. Hypothalamic dysfunction in Parkinson's disease patients.  Acta Med Hung. 1994;  50 3-13
    PubMedSearch in Google Scholar
  • 11 Segarra AB, Ramirez M, Banegas I, Hermoso F, Vargas F, Vives F, Alba F, de Gasparo M, Prieto I. Influence of thyroid disorders on kidney angiotensinase activity.  Horm Metab Res. 2006;  38 48-52
    Thieme ConnectPubMedSearch in Google Scholar
  • 12 Jenkins TA, Wong JY, Howells DW, Mendelsohn FA, Chai SY. Effect of chronic angiotensin-converting enzyme inhibition on striatal dopamine content in the MPTP-treated mouse.  J Neurochem. 1999;  73 214-219
    CrossrefPubMedSearch in Google Scholar

Correspondence

Francisco Vives

Institute of Neuroscience “Federico Oloriz” and Department of Physiology·University of Granada

Avda. Madrid, 11

18012 Granada

Spain

Phone: +34/958/24 35 25

Fax: +34/958/24 90 15

Email: fvives@ugr.es